Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.08 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2019-03-07
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was 5.15 CAD/shares, a 66.12% decline from fiscal 2015.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was 15.20 CAD/shares, a 11.52% increase from fiscal 2014.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was 13.63 CAD/shares, a 234.07% increase from fiscal 2013.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2013 was 4.08 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2016-12-31 | 5.15 CAD/shares 10-K · filed 2017-03-22 |
| 2015-12-31 | 15.20 CAD/shares 10-K · filed 2016-03-09 |
| 2014-12-31 | 13.63 CAD/shares 10-K · filed 2015-03-13 |
| 2013-12-31 | 4.08 CAD/shares 10-K · filed 2014-03-28 |
| 2012-12-31 | 2.43 CAD/shares 20-F · filed 2013-03-27 |
| 2011-12-31 | 0.22 CAD/shares 20-F · filed 2013-03-27 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2018-12-31 | $4.08 10-K · filed 2019-03-07 |
| 2017-12-31 | $2.15 10-K · filed 2018-03-16 |
| 2016-12-31 | $3.89 10-K · filed 2017-03-22 |
| 2015-12-31 | $11.89 10-K · filed 2016-03-09 |
| 2014-12-31 | $12.34 10-K · filed 2015-03-13 |
| 2013-12-31 | $5.30 10-K · filed 2014-03-28 |
| 2012-12-31 | $2.51 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |